Sort Through Meds for Managing Hemophilia

New meds Jivi (JIH-vee) and Rebinyn (reh-bee-NYNE) will raise questions about managing bleeding in hemophilia patients.

Jivi (recombinant PEGylated factor VIII) will be for hemophilia A. It will compete with other long-acting (Adynovate, Eloctate, etc) and short-acting (Kogenate FS, Recombinate, etc) factor VIII products.

Rebinyn (recombinant glycoPEGylated factor IX) is for the less common hemophilia B. It's an alternative to long-acting (Alprolix, Idelvion, etc) or short-acting (BeneFix, Ixinity, etc) factor IX products.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote